Home › NDC Lookup › Ingredients › Nickel Sulfate, Potassium Bromide, And F... › 61480-0255-05
⚪image loading
(from DailyMed)

Psorizide Forte Nickel Sulfate, Potassium Bromide, and Fumaric Acid 1 [hp_X]/1; 1 [hp_X]/1; 1 [hp_X]/1 Tablet, 90-count — NDC 61480-255-05 (Billing 61480-0255-05)

by PLYMOUTH HEALTHCARE PRODUCTS LLC · 90 TABLET in 1 BOTTLE

This is a package of 90 tablets of Psorizide Forte Nickel Sulfate, Potassium Bromide, and Fumaric Acid 1 [hp_X]/1; 1 [hp_X]/1; 1 [hp_X]/1 Tablet from PLYMOUTH HEALTHCARE PRODUCTS LLC, marketed since Nov 2001 and currently FDA-listed. It is this product's only package size.

NDC 61480-0255-05
🏷️ FDA NDC (as labeled) 61480-255-05 billing pads the product segment with a zero
Rx only On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 61480-255-05 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
61480 labeler · 255 product · 05 package
Package marketed since
Nov 15, 2001
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
90 EA per package
Barcode (UPC-A, from the NDC)
3 6148025505 3
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 61480-255-05
Product NDC 61480-255
11-digit billing NDC 61480025505
NCPDP billing unit EA — each (per item)
UNII 4FLT4T3WUN, OSD78555ZM, 88XHZ13131
SPL Set ID 7896794a-60bd-4dfa-abfe-aa29aaa6f74d
DEA schedule Non-controlled
Marketing category UNAPPROVED HOMEOPATHIC
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2001-11-15
Route ORAL
Dosage form TABLET
Substance NICKEL SULFATE; POTASSIUM BROMIDE; FUMARIC ACID

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 99870010000300
GPI class Psorizide Forte
GCN Seq No 048716
GCN 14662
HICL code 022913
Ingredient (HICL) Nickel Su/Pot Bromide/Fumaric
HIC1 code C
Therapeutic class — broad (HIC1) Electrolyte Balance/Metabolism/Nutrition
HIC2 code C5
Therapeutic class — intermediate (HIC2) Carbohydrates And/Or Proteins
HIC3 code C5F
Therapeutic class — specific (HIC3) Dietary Supplement, Miscellaneous
AHFS code 92:92.00.00
AHFS class Other Miscellaneous Therapeutic Agents
FDB label name PSORIZIDE FORTE TABLET
FDB brand name Psorizide Forte
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 048716
  • GCN: 14662
  • GPI-14 (Medi-Span): 99870010000300
  • HICL (First Databank): 022913
  • AHFS class code: 92:92.00.00
Why two NDCs? The FDA registers this code as 61480-255-05 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 61480-0255-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name PSORIZIDE FORTE TABLET Ingredient Nickel Su/Pot Bromide/Fumaric
🧪 What is this product?

Psorizide Forte is an oral tablet marketed as a homeopathic product containing fumaric acid, nickel sulfate, and potassium bromide. In homeopathic practice, these substances are traditionally used to address skin conditions, though homeopathic products are marketed based on traditional use rather than FDA-evaluated effectiveness. This product is not approved by the FDA and is classified as an unapproved homeopathic medicine.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eachPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
61480-0255-05 You're viewing this Main listing 90 TABLET in 1 BOTTLE 2001-11-15 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Psorizide Forte 1 [hp_X]/1; 1 [hp_X]/1; 1 [hp_X]this 61480-0255-05 PLYMOUTH 90 tablets — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2001
On the market since
Nov 2001
📍
2026
Currently FDA-listed
25 years listed
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
ShapeRound
ImprintLL
Size11 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerPLYMOUTH HEALTHCARE PRODUCTS LLC
Labeler code61480
First marketedNov 2001
Product typeHuman Prescription Drug
Portfolio7 products on file

More NDCs from PLYMOUTH HEALTHCARE PRODUCTS LLC labeler code 61480

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 🔬 Clinical Studies 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📚 References 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 52 words ▾

INDICATIONS PSORIZIDE ® Forte is indicated for the treatment of contact dermatitis due to nickel (metal/jewelry allergy,) dyshidrotic hand/foot eczema, and mild to severe psoriasis. It has been found to work well with a variety of combination therapies. Eczema, seborrhea and a variety of chronic pruritic inflammatory dermatoses generally respond well also.

⏱️ Dosage and Administration 220 words ▾

DOSAGE AND ADMINISTRATION Absorption of nickel sulphate is variable among individuals . For maximum absorption, tablets should be taken orally at the beginning of the day (or any convenient time after having taken nothing but water for at least 7 hours). Take nothing but water for one hour after taking medication to aid absorption.

Weight Starting Dose Max Daily Dose 40-80 lbs ½ tablet 1 ½ tablet 80-120 lbs 1 tablet 3 tablets 120-160 lbs 1 ½ tablets 4 ½ tablets 160-200 lbs 2 tablets 6 tablets 200-240 lbs 2 ½ tablets 7 ½ tablets Over 240 lbs 3 tablets 9 tablets In the setting of renal impairment Dosage should be adjusted and serum nickel and bromide levels should be followed. Steady state trough level should be drawn prior to ingesting the day's dose after one week of dosing or at appropriate intervals. Target trough serum nickel level is 30-60 mcg/L.

(Caution: post dose peak levels are unreliable.) Maintenance phase In order to maintain symptomatic relief, medication may be continued at the same or reduced initial phase dose level. Treatment duration depends on the individual. For allergic nickel dermatitis, continue 2 tablets 1 hour prior to breakfast for weeks 7 – 16.

(Refer to Hypersensitivity section above). Some patients may require continued or intermittent repeated treatment to maintain nickel desensitization.

⛔ Contraindications 32 words ▾

CONTRAINDICATIONS Although there are no known contraindications, patients who are allergic to any PSORIZIDE ® Forte ingredient should consult a physician prior to taking the medication. (Refer to Section on Hypersensitivity )

⚠️ Warnings 53 words ▾

WARNING Do not use if imprinted seal under bottle cap is missing or broken. Do not use if pregnant or nursing. If allergic to nickel or metal objects such as jewelry, see PRECAUTIONS for hypersensitivity information. Lactose intolerant patients may have gastrointestinal difficulty. This has very rarely been reported at the doses used.

🤒 Adverse Reactions 23 words ▾

ADVERSE REACTIONS PSORIZIDE ® Forte contains low doses of active ingredients. Therefore there are minimal known side effects. (see PRECAUTIONS for hypersensitivity information)

🔄 Drug Interactions 8 words ▾

Drug Interactions There are no known drug interactions.

🤰 Pregnancy 26 words ▾

Pregnancy Pregnancy category C Animal reproduction studies have not been conducted with PSORIZIDE ® Forte. PSORIZIDE ® Forte should not be given to a pregnant woman.

🧒 Pediatric Use 11 words ▾

Pediatric use Carefully adjust dosage to weight when treating young children.

🆘 Overdosage 166 words ▾

OVERDOSAGE Fumaric acid toxicity The oral rat LD 50 is 9300mg/kg. 26 This is 3800 times the maximum dose recommended for PSORIZIDE ® Forte. Potassium bromide toxicity Indications of toxicity due to oral overdosage of bromide may include nausea and vomiting, apathy, disturbed coordination, loss of memory, drowsiness, loss of emotional control, agitation, hallucination, tremors, depressed reflexes, stupor, and coma.

Acute toxic reactions in humans have been reported at doses as low as 1000mg. 31 This level is 67 times the dose received in one tablet of PSORIZIDE ® Forte. Nickel sulphate toxicity The oral rat LD 50 for nickel sulphate hexahydrate is 275mg/kg.

29 Symptoms of toxicity due to oral overdosage of nickel sulphate may include nausea, vomiting, abdominal discomfort, diarrhea, giddiness, lassitude, headaches, cough, and shortness of breath. 30 The lowest observed transitory toxic effects from human ingestion of soluble nickel salts is approximately 8 mg nickel/kg body weight. 30 This is 138 times the maximum dose recommended for PSORIZIDE ® Forte (see below).

🧬 Clinical Pharmacology ~2 min read ▾

CLINICAL PHARMACOLOGY The active ingredients in PSORIZIDE ® Forte are simple biochemical compounds. The exact mechanism of action is unknown; however, it is believed PSORIZIDE ® Forte addresses a primary genetic biochemical defect. 5 FUMARIC ACID is a naturally occurring four carbon organic acid important in the Krebs cycle.

This biochemical pathway is of central importance to energy production. Each tablet contains approximately 30 mg fumaric acid (calculated). Fumaric Acid has many uses, including use as a food additive (GRAS) and as a chelating agent.

13 The use of fumaric acid and its derivatives (esters) as a treatment for psoriasis is increasing worldwide. 14-20 Very little is known about its clinical pharmacology; however, dose dependant inhibitory effects on keratinocyte proliferation have been demonstrated. 16,21 POTASSIUM BROMIDE dissolves and dissociates in the digestive tract into its ionic constituents.

Each tablet contains approximately 15 mg bromide (calculated). Ionic bromide is rapidly and completely absorbed from the intestine and distributed almost exclusively into the extracellular fluids. 11,12 Bromide is eliminated by the kidneys and the elimination half-life is 11-12 days. "Once a day" dosing will lead to a steady state concentration in about seven weeks.

11 NICKEL SULPHATE dissolves and dissociates in the digestive tract into its ionic constituents. Each tablet contains approximately 1.0 mg of ionic nickel (calculated). According to studies, 15% to 50% of ionic nickel is absorbed on a fasted stomach.

6 Food markedly decreases the rate and extent of nickel absorption. 7,8 Clinical studies show that serum concentrations of nickel are variable among patients after administering the same dose. 9 Peak serum nickel concentration is reached about two hours after oral administration. "Once a day" dosing leads to steady state serum concentrations in approximately one week.

Nickel is in its highly stable divalent cation state and is therefore not expected to be metabolized to any significant degree in the body. Absorbed nickel is primarily excreted in the urine and elimination half-life is about 21 hours. 7,9 Renal clearance is rapid and efficient, and nickel does not accumulate in the body.

10

📦 How Supplied / Storage and Handling 34 words ▾

HOW SUPPLIED Scored tablets, off white in color with green speckles, with imprinted on one side and a score on the other , in child-resistant and tamperresistant bottles of 90 . NDC 61480-255-05 Symbol

📋 Description 104 words ▾

DESCRIPTION PSORIZIDE ® Forte is a biochemical homeopathic medication indicated for the treatment of contact dermatitis due to nickel (metal/jewelry allergy), dyshidrotic hand/foot eczema, and mild to severe psoriasis . 1-3 The active ingredients in each PSORIZIDE ® Forte tablet consist of the following: Fumaric Acid (Fumaricum Acidum) 1X, Potassium Bromide (Kali Bromatum) 1X, and Nickel Sulphate (Niccolum Sulphuricum) 1X. These drug ingredients are listed in the Homoeopathic Pharmacopoeia of the United States (HPUS).

4 Inactive ingredients: Lactose and Magnesium Stearate. Pharmacological Class: Homeopathic drug. Dosage form: Oral 600 mg scored tablet.

May be swallowed whole, chewed or dissolved in the mouth and swallowed.

💬 Information for Patients 75 words ▾

Information for patients Patients using PSORIZIDE ® Forte should receive the following information and instructions: This medication is to be used only as directed by a physician. It is important to take orally at the beginning of the day on an empty stomach (or any convenient time after having taken nothing but water for at least 7 hours) and to eat or drink nothing but water for one hour afterwards to avoid interference with absorption.

⚠️ Precautions ~3 min read ▾

PRECAUTIONS Carefully adjust dosage to weight when treating young children. Use cautiously in setting of kidney disease. (see Dosage and Administration ) If skin rash appears or if nervous symptoms persist, recur frequently, or are unusual, discontinue use.

Hypersensitivity Caution should be used when administering to patients with a history of contact sensitivity to nickel (common metal exposure). Nickel allergy may be confirmed by a positive nickel patch test. Most patients with positive nickel allergy history or a positive nickel patch test do not have any untoward reaction to administration of PSORIZIDE ® Forte.

However, if there is a history of nickel sensitivity, begin with a very low dose and slowly increase over a period of six weeks as tolerated. Progressive G.I. absorption allows desensitization to occur. 8 Nickel desensitization schedule: Week Amount of Time to Take Medication Prior to Breakfast Week 1 1 tablet With Breakfast Week 2 1 tablet 15 min Prior Week 3 1 tablet 30 min Prior Week 4 1 tablet 45 min Prior Week 5 1 tablet 1 hour Prior Week 6 and thereon 2 tablets 1 hour Prior If new pruritic rashes occur or persist, discontinue PSORIZIDE ® Forte and treat appropriately.

Do not use if there is a history of extra-cutaneous hypersensitivity to nickel or any ingredient in PSORIZIDE ® Forte. Information for patients Patients using PSORIZIDE ® Forte should receive the following information and instructions: This medication is to be used only as directed by a physician. It is important to take orally at the beginning of the day on an empty stomach (or any convenient time after having taken nothing but water for at least 7 hours) and to eat or drink nothing but water for one hour afterwards to avoid interference with absorption.

Drug Interactions There are no known drug interactions. Carcinogenesis, mutagenesis, and impairment of fertility No studies have been done on the carcinogenesis, mutagenesis, or impairment of fertility of PSORIZIDE ® Forte. No carcinogenesis or mutagenesis has been reported in multiple animal studies for oral administration of fumaric acid and soluble nickel and bromide salts (active ingredients) even at very high doses.

24-27 Effects of fumaric acid It is not listed as a carcinogen by ACGIH, IARC, NIOSH, NTP, or OSHA. 26 It is a GRAS substance (generally recognized as safe) and is commonly used in food processing. Effects of soluble potassium bromide KBr is not listed as a carcinogen by the NTP, IARC, and OSHA.

28 Effects of soluble nickel sulphate Studies on experimental animals have never indicated that nickel, at any dose, is a carcinogen when introduced to the body orally. Furthermore, Nickel sulphate and other highly water soluble nickel salts, have never been known to induce carcinogenesis via any route of introduction including: oral, inhalation, cutaneous, IM, or IP. 10-12,27 No adverse effects were noted on fertility or reproduction in a 3-generational study of albino Wistar rats fed up to 1000 ppm Ni per day, which is equivalent to 50 mg/kg body weight per day Ni.

27 Pregnancy Pregnancy category C Animal reproduction studies have not been conducted with PSORIZIDE ® Forte. PSORIZIDE ® Forte should not be given to a pregnant woman. Nursing mothers It is not known whether this drug is secreted in human milk.

However, since many drugs are secreted in human milk, caution should be exercised when PSORIZIDE ® Forte is administered to a nursing woman. Pediatric use Carefully adjust dosage to weight when treating young children.

🍼 Nursing Mothers 37 words ▾

Nursing mothers It is not known whether this drug is secreted in human milk. However, since many drugs are secreted in human milk, caution should be exercised when PSORIZIDE ® Forte is administered to a nursing woman.

🔬 Clinical Studies 45 words ▾

CLINICAL STUDIES A variety of controlled clinical studies have been performed using various sources of both nickel and bromide in over 300 subjects. Clinical efficacy and safety have been documented in a significant number of subjects. Published and unpublished reports are available upon request. 22,23,32

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 54 words ▾

Carcinogenesis, mutagenesis, and impairment of fertility No studies have been done on the carcinogenesis, mutagenesis, or impairment of fertility of PSORIZIDE ® Forte. No carcinogenesis or mutagenesis has been reported in multiple animal studies for oral administration of fumaric acid and soluble nickel and bromide salts (active ingredients) even at very high doses. 24-27

📚 References ~3 min read ▾

REFERENCES Reckeweg, Hans-Heinrich, Materia Medica, 1983, first English edition. Boericke, William, Materia Medica with Reperatory, 1927, ninth edition. Clarke, John Henry, A Dictionary of Practical Materia Medica, 1921, reprint edition 1996.

The Homeopathic Pharmacopoeia of the United States (HPUS), December 2000 edition, Falls Church, Virginia. Kiehl R, Ionescu G, A Defective Purine Nucleotide Synthesis Pathway in Psoriatic Patients, Acta Derm Venereol (stockh), 1992, 72:253-255. Sunderman FW Jr.

Biological monitoring of nickel in humans. Scand J. Work Environ Health 1993; 19 suppl 1:34-38.

Sunderman FW Jr., Hopfer SM, Sweeney KR, Marcus AH, Most BM, Creason J. Ncikel absorption and kinetics in human volunteers. P.S.E.B.M.

1989; 191:5-11. Solomons NW, Viteri F, Shuler TR, Nielsen FH, Bioavailability of nickel in man: Effects of foods and chemically-defined dietary constituents on the absorption of inorganic nickel. J Nutr 1982; 112:39-50.

Christensen OB, Lagesson V. Nickel concentration of blood and urine after oral administration. Annals of Clinical and Laboratory Science 1981;2(2);119-125.

Nielsen FH. Is nickel nutritionally important? Nutrition Today 1993; 28 (1):14-19.

Vaiseman N. Koren G. Pencharz P.

Pharmacokinetics of oral and intravenous bromide in normal volunteers. Clinical Toxicology 1986;24(5):403-413. Van Leeuwen FXR, Sangster B.

The toxicology of bromide ion. CRC Critical Reviews in Toxicology 1987; 18(3): 189-213. Wade A, Weller PJ Handbook of Pharmaceutical Excipients 2 nd edition, American Pharmaceutical Association, 1994.

Parfitts K, editor, Martindale: The complete Drug Reference, 1999, 32 nd edition, Pharmaceutical Press, London. Nieboer C, et al, Fumaric Acid Therapy in Psoriasis, Dermatologica, 1990; 181:33-37 Mrowietz U, et al, Treatment of severe psoriasis with fumaric acid esters: scientific background and guidelines for therapeutic use, Br J Dermatol 1999;141:424-429. Mrowietz U, et al, Treatment of psoriasis with fumaric acid esters, Br J Dermatol 1998; 138:456-460.

Kolbach DN, Nieboer C, Fumaric Acid Therapy in Psoriasis, J Am Acad Dermatol 1992; 27: 769-771. Altmeyer P, et al, Antipsoriatic Effect of Fumaric Acid Derivatives, J Am Acad Dermatol 1994; 30:997-981. Nugteren – Huying WM, etal, Fumaric Acid Therapy for Psoriasis, J Am Acad Dermatol 1990; 22: 311-312.

Thio, HB, et al, Fumaric Acid Derivatives… Inhibit the proliferation of Human Keratinocytes, Br J Dermatol 1994; 131: 856-866. Smith SA. Oral supplementation of nickel and bromide in psoriasis vulgaris using nickel sulfate and sodium bromide.

1995 (unpublished report). Smith SA, et al, Improvement of Psoriasis Vulgaris with Oral Nickel Dibromide. Archives of Dermatology 1997; 133:661-663.

US EPA, Environmental Criteria and Assessment Office, Office of Health and Environmental Assessment. Drinking water quantification of toxicological effects for nickel. ECAO-CIN-443.

US FDA, Center for Food Safety and Applied Nutrition. Guidance document for nickel in shellfish. 1993.

IARC Monograph on the Evaluation of Carcinogenic Risk of Chemicals to Man. IRC Publication #11, Lyon, France 1976. MSDS Fumaric Acid.

Acros Organics, Fair Lawn, N.J., Revised 8/2000. Ambrose AM, Larson PS, Borsellaca FJ, and Hennigar GR, JR. Long term toxicologic assessment of nickel in rats and dogs.

Journal of Food and Science and Technology 1976;13:181-187. MSDS Sheet No. 247 Potassium Bromide, Schenectady, NY: Genium Publishing Corp 1991.

MSDS Sheet No. 37 Nickel Sulfate, Schenectady, NY: Genium Publishing Corp 1993. Sunderman FW Jr., Dingle B, Hopfer SM, and Swift T.

Acute nickel toxicity in electroplating workers who accidentally ingested a solution of nickel sulfate and nickel chloride. American Journal of Industrial Medicine 1988; 14:257-266. Martindale: The Extra Pharmacopoeia, 27 th ed.

Wade A, editor. The Pharmaceutical Press: London, 1977, pp 273-274. Smith SA, Baker AE, etal.

Effective Treatment of Seborrheic Dermatitis Using a Low Dose, Oral Homeopathic Medicat… [Excerpted — this section continues on DailyMed.]

📄 Package Label / Principal Display Panel 28 words ▾

PRINCIPAL DISPLAY PANEL - 90 Tablet Label NDC 61480-255-05 Homeopathic Medication PSORIZIDE ® Forte Indicated for treatment of PSORIASIS 90 Tablets Principal Display Panel - 90 Tablet Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

About this NDC listing & data coverage

Finished prescription product Homeopathic listing

About homeopathic listings

Psorizide Forte Nickel Sulfate, Potassium Bromide, and Fumaric Acid 1 [hp_X]/1; 1 [hp_X]/1; 1 [hp_X]/1 TABLET is listed under the homeopathic marketing category. An NDC listing in this category does not by itself establish FDA approval, and FDA does not evaluate homeopathic products for effectiveness. This page reports the listing data as published.

What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos — Not published for this NDC No photo available yet for this listing.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Unapproved Homeopathic". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by PLYMOUTH HEALTHCARE PRODUCTS LLC. Listing status can change — the directory data on this page refreshes weekly.
Who lists this product with the FDA?
PLYMOUTH HEALTHCARE PRODUCTS LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 61480-0145-63 · PLYMOUTH 61481-0036-02 · Wilc →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.